Featured Editorial

  1. Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery 7/22/2026

    As RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.

  2. Soliman Says… 5 Questions Every RNA Platform Must Answer Before Investors Write The Check 7/21/2026

    A practical framework for evaluating whether an RNA company has the science, strategy, scalability, and discipline to become a lasting platform.

  3. Building A Self-Driving Lab For LNP Development 7/20/2026

    With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.

  4. Beyond Vaccines: Can RNA Sense Gases? 7/20/2026

    Could RNA sense its environment? A new hypothesis explores how RNA may detect temperature and gases, inspiring smarter, adaptive RNA therapeutics.

  5. Decoding RNA's Circular Decisions: How HNRNPD Shapes circRNA Biogenesis And RNA Fate 7/17/2026

    How do cells decide between circular and linear RNA? New insights into HNRNPD reveal mechanisms that could improve the design of future circRNA therapeutics.

  6. 5 Critical Regulatory Topics To Watch In The Oligo Sector 7/16/2026

    Though our guidances have helped us achieve upwards of 20 commercially approved oligo products, as I listened to GSK’s director of CMC policy and advocacy, Katie Duncan, present at TIDES, it struck me just how far we have yet to come. Here, I single out a few of the biggest topics of regulatory discussion shaping the oligo therapeutics market.

  7. Beyond Gene Silencing: Harnessing Regulatory RNAs To Increase Gene Expression In Haploinsufficient Disease 7/16/2026

    Can RNA therapeutics increase — not silence — gene expression? Regulatory RNA-targeting ASOs may redefine treatment for haploinsufficient diseases.

  8. Beyond The m⁷G Cap: How Non-Canonical RNA Capping Could Expand RNA Therapeutics 7/16/2026

    Newly discovered non-canonical RNA caps are reshaping RNA biology and could inspire the next generation of more precise, programmable RNA therapeutics.

  9. Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches 7/14/2026

    This article highlights government-funded resources available to de-risk nanomedicines, reviews principles of immunotoxicity testing, and discusses emerging methodologies.

  10. Bridging The Atlantic: A European Executive's Guide To Entering The U.S. RNA Market (Pt. 1) 7/13/2026

    A practical roadmap for European biotech leaders navigating FDA expectations, market entry, and the strategic decisions that shape U.S. expansion.